

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

Evaluation of the Effect of Using Mouthwash Solution Containing Hydroalcoholic Extract of Pomegranate and Turmeric on Oral Mucositis Due to Chemotherapy in Cancer Patients, a Triple blind, Randomized, Controlled Trial

Protocol summary

Study aim

The effect of pomegranate and turmeric mouthwash on chemotherapy-induced mucositis

Design

Clinical trial with control group, with parallel groups, three-way blind, randomized, phase 2 on 60 patients. A table of random numbers is used for randomization.

Settings and conduct

The study will be performed on 60 patients undergoing chemotherapy at Shahid Rahimi Hospital in Khorramabad. The control group continued with placebo mouthwash and the intervention group continued with pomegranate and turmeric mouthwash. Both groups also accepted routine treatment. It was then tested by a specific person on days 0, 7 and 14 of the intervention. In order to blind the researcher and other people involved in the study, the random grouping of participants will be assigned to one of the nurses, and in order to blind the patients, the mouthwash will contain the same extract and placebo.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients 18 to 65 years Patients are able to complete the questionnaire Absence of serious dental problems and damage to the oral mucosa Do not use dentures Do not use anti-inflammatory and other mouthwash solutions during research No other systemic diseases No history of smoking, drugs and alcohol No oral candidiasis or herpes simplex Do not use cryotherapy for six weeks before the study Exclusion criteria: Patient dissatisfaction History of allergies to turmeric and pomegranate, lidocaine, antacids, diphenhydramine and dexamethasone Inability of the patient to implement the treatment protocol Patient death due to failure to respond to anticancer therapy Combination therapies such as radiation therapy

Intervention groups

Intervention group: routine mouthwash plus mouthwash containing pomegranate and turmeric extract Control group: routine mouthwash plus placebo mouthwash

Main outcome variables

Degree of mucositis

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200721048159N1**

Registration date: **2021-04-10, 1400/01/21**

Registration timing: **prospective**

Last update: **2021-04-10, 1400/01/21**

Update count: **0**

Registration date

2021-04-10, 1400/01/21

Registrant information

Name

Forouzan Ahmadpour

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 66 3312 0239

Email address

ahmadpoor.f@lums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-05-17, 1400/02/27

Expected recruitment end date

2021-11-18, 1400/08/27

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the Effect of Using Mouthwash Solution Containing Hydroalcoholic Extract of Pomegranate and Turmeric on Oral Mucositis Due to Chemotherapy in Cancer Patients, a Triple blind, Randomized, Controlled Trial

Public title

Evaluation of the Effect of Pomegranate and Turmeric Mouthwash on Oral Mucositis Due to Chemotherapy

Purpose

Supportive

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients in the age range of 18 to 65 years Cancer patients with chemotherapy-induced oral inflammation Patients are able to complete a questionnaire and collaborate with the researcher Absence of serious dental problems or teeth damaging the oral mucosa or sharp fillings Do not use dentures Do not use anti-inflammatory and other mouthwash solutions during research No other systemic diseases No history of smoking, drugs and alcohol No oral candidiasis (fungus) or herpes simplex (virus) Do not use cryotherapy for six weeks before the study

Exclusion criteria:

Dissatisfaction with participating in the study Participate in another clinical trial at the same time History of allergies to turmeric and pomegranate, lidocaine, antacids, diphenhydramine and dexamethasone Inability of the patient to implement the treatment protocol Patient death due to failure to respond to anticancer therapy Combination therapies such as radiation therapy

AgeFrom **18 years** old to **65 years** old**Gender**

Both

Phase

N/A

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample sizeTarget sample size: **60****Randomization (investigator's opinion)**

Randomized

Randomization description

Samples are used by stratified random blocking method (classes are intended to match the two groups in terms

of disease grades so that patients with grade 1 and 2 in one class and patients with grade 3 and 4 in the other class) to two) An equal group of control and intervention will be assigned. The method of allocating samples to the two groups will be that considering the mucosal grade as a class, the method of 4 random blocks will be used to assign patients to two groups A (intervention) and group B (control). To do this, first write a list of blocks and assign numbers to them. (AABB (1) - ABAB (2) -ABBA (3) -BBAA (4) - BABA (5) - BAAB (6)) Then using From the table of random numbers and randomly selected numbers between 1 and 6 and finally the list of treatment allocation will be formed based on a sequence of letters A and B.

Blinding (investigator's opinion)

Triple blinded

Blinding description

This is a Triple-Blind Study and the blinding method is such that the researcher and the participating patients and data analyst will be unaware of which participant is in which group. In order to blind the researcher, random grouping of participants and prescribing mouthwash to them will be assigned to one of the ward doctors or nurses who has no role in the trial. In order to blind the participating patients, mouthwash containing extract and placebo mouthwash will taste as much as possible. And will have a similar appearance and will be prescribed in identical bottles. None of the members of the Data Safety and Supervision Committee, as well as the person evaluating the outcome and analyzing the data, will have a role in the randomization and use of mouthwash by participating patients and will not be informed which mouthwash each patient will use.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Lorestan University of Medical Sciences

Street address

Naser Khosrow Square, Roudaki St., Chaghervand Alley, No. 10

City

khorram abad

Province

Lorestan

Postal code

1234567898657678

Approval date

2021-03-09, 1399/12/19

Ethics committee reference number

IR.LUMS.REC.1399.363

Health conditions studied**1****Description of health condition studied**

Oral mucositis due to antineoplastic therapy

ICD-10 code

K12.31

ICD-10 code description

Oral mucositis (ulcerative) due to antineoplastic therapy

Primary outcomes**1****Description**

Grade of mucositis based on WHO scale

Timepoint

Evaluation of grade of mucositis at the beginning of the study, 7 and 14 days after mouthwash containing pomegranate and turmeric extract

Method of measurement

Standard questionnaire and patient examination

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Intervention group Herbal mouthwash containing 6.25% hydroalcoholic extract of pomegranate peel and 0.1% hydroalcoholic extract of turmeric, once every 6 hours, 30 drops in water to reach a volume of 10 ml and hold in the mouth for 2 minutes and then gargle They will swallow. The patients will receive herbal mouthwash for a week in addition to routine treatment.

Category

Treatment - Drugs

2**Description**

Control group: The control group poured 30 drops of placebo into the mouth every 6 hours until it reached a volume of 10 ml and was kept in the mouth for 2 minutes, then gargled and swallowed. The patients will receive placebo mouthwash for a week in addition to routine treatment.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Shahid Rahimi Hospital

Full name of responsible person

Forouzan Ahmadpour

Street address

Shahid Seyed Fakhreddin Rahimi Hospital, not far from Safavid Bridge, Mojahedin Street, Azadi Square

City

Khorramabad

Province

Lorestan

Postal code

6813816314

Phone

+98 66 1223 6141

Email

rahimi@lums.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Khoram-Abad University of Medical Sciences

Full name of responsible person

Forouzan Ahmadpour

Street address

Shahid Seyed Fakhreddin Rahimi Hospital, not far from Safavid Bridge, Mojahedin Street, Azadi Square

City

Khorramabad

Province

Lorestan

Postal code

6813816314

Phone

+98 66 1223 6141

Email

rahimi@lums.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Khorramabad University of Medical Sciences

Proportion provided by this source

30

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Khoram-Abad University of Medical Sciences

Full name of responsible person

Forouzan Ahmadpour

Position

Assistant professor of clinical pharmacy

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Kamalvand, 4 km of Khorramabad road

City

Khoramabad

Province

Lorestan

Postal code

12467865432453

Phone

+98 66 3312 0239

Fax**Email**

ahmadpourforoz@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Khoram-Abad University of Medical Sciences

Full name of responsible person

Forouzan Ahmadpour

Position

Assistant professor of clinical pharmacy

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Kamalvand, 4 km of Khorramabad road

City

Khoramabad

Province

Lorestan

Postal code

12467865432453

Phone

+98 66 3312 0239

Fax**Email**

ahmadpourforoz@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Khoram-Abad University of Medical Sciences

Full name of responsible person

Forouzan Ahmadpour

Position

Assistant professor of clinical pharmacy

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Kamalvand, 4 km of Khorramabad road

City

Khoramabad

Province

Lorestan

Postal code

12467865432453

Phone

+98 66 3312 0239

Fax**Email**

ahmadpourforoz@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available